GSK files complaint over violation of Tivicay patent rights in Russia

GlaxoSmithKline Trading, the distribution division of the British pharma major GSK (LSE: GSK), has filed a complaint to the Russian anti-trust regulator FAS on the recent auction for state procurements of GSK’s anti-HIV drug Tivicay (dolutegravir).

As a result of this auction, the winner of the tender for the first time became the Russian company BSS, which offered the lower price for the drug, which still remains under patent protection in Russia, reports The Pharma Letter’s local correspondent.

Due to the GSK complaint, signing of the contract between BSS and the Russian state was suspended.